Leonard Zehr, Author at BioTuesdays

Feature

bioAffinity rolling out CyPath for early detection of lung cancer

bioAffinity Technologies (NASDAQ:BIAF) is rolling out CyPath Lung, an accurate, non-invasive and cost-effective test for the early detection of lung cancer, in the U.S. Southwest before a staged nationwide launch.

March 14, 2023

Feature

Conavi’s Novasight shines new light on coronary interventions

Privately-held Conavi Medical’s Novasight Hybrid System represents a breakthrough imaging platform for use by interventional cardiologists during common minimally invasive heart procedures.

March 7, 2023

Feature

AUM Biosciences focused on reversing cancer resistance

With two clinical and two preclinical assets, AUM Biosciences is developing precision oncology therapeutics designed to reverse cancer resistance through multi-targeting approaches.

February 28, 2023

Feature

Cognition Therapeutics focused on modifying degenerative disorders

As the recipient of more than $170-million of non-dilutive grant funding, Cognition Therapeutics (NASDAQ:CGTX) is developing disease-modifying medicines for neurodegenerative disorders, such as Alzheimer's disease (AD)...

February 21, 2023

Feature

Context Therapeutics advancing pipeline for female cancers and other tumors

Martin Lehr likes to use a baseball analogy to describe his company’s two cancer programs. “CTIM-76 is our hot young rookie with home run potential at every bat while ONA-XR is our veteran who consistently gets on...

February 14, 2023

Feature

Indaptus advancing Decoy20 against metastatic solid tumors

Indaptus Therapeutics (NASDAQ:INDP) is conducting a first-in-human, dose escalation Phase 1 study of its lead compound, Decoy20, in patients with advanced metastatic solid tumors where currently approved therapies have...

February 7, 2023

Developments

Theralase to present Phase 2 NMIBC interim data at AUA meeting

The American Urology Association has accepted for a moderated poster presentation at its annual meeting Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) interim data from its Phase 2 Bacillus Calmette Guerin unresponsive...

February 2, 2023

Feature

Stephanie Willerth talks up award winning bioink start-up

As CEO and co-founder of closely-held Axolotl Biosciences, Stephanie Willerth, Ph.D., also is a full professor of biomedical engineering at the University of Victoria, British Columbia, where she runs a research lab...

January 31, 2023

Feature

Azura targeting ophthalmic keratolytics for ocular surface diseases

After posting positive Phase 2b results in November, Azura Ophthalmics plans to launch a Phase 3 registration trial in mid-2023 with its lead ointment, AZR-MD-001, for the treatment of meibomian gland dysfunction (MGD)...

January 24, 2023

Developments

Hepion posts positive preclinical results in multiple myeloma expanding rencofilstat’s anti-cancer potential

Hepion Pharmaceuticals (NASDAQ:HEPA) announced positive results of preclinical studies examining rencofilstat as a potential therapeutic for multiple myeloma (MM). Rencofilstat exerted anti-cancer activity across a...

January 18, 2023

Author - Leonard Zehr

bioAffinity rolling out CyPath for early detection of lung cancer

Conavi’s Novasight shines new light on coronary interventions

AUM Biosciences focused on reversing cancer resistance

Cognition Therapeutics focused on modifying degenerative disorders

Context Therapeutics advancing pipeline for female cancers and other tumors

Indaptus advancing Decoy20 against metastatic solid tumors

Theralase to present Phase 2 NMIBC interim data at AUA meeting

Stephanie Willerth talks up award winning bioink start-up

Azura targeting ophthalmic keratolytics for ocular surface diseases

Hepion posts positive preclinical results in multiple myeloma expanding rencofilstat’s anti-cancer potential

General

More